Clinical trials: CD
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT03105128
- Testing
- risankizumab IV, risankizumab SC
- Where
- 475 sites in United States, Argentina and 42 more
- Volunteers
- 931 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis)
The purpose of the study is determine if a plant-based resistant starch that is optimized for the individual will target the underlying cause of inflammatory bowel disease and restore a "healthier" gut microbiome in pediatric…
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT04522271
- Testing
- Resistant Starch
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Children's Hospital of Eastern Ontario
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie
Crohn Disease
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
The purpose of this study is to assess the safety and efficacy of tulisokibart (MK-7240) in participants with moderately to severely active Crohn's Disease.
- Trial name
- APOLLO-CD (NCT05013905)
- Testing
- Tulisokibart, Companion Diagnostic (CDx)
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 55 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Crohn's Disease
Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
The purpose of this clinical trial is to evaluate long-term safety and efficacy in patients who has history of FURESTEM-CD injection at least once.
- Trial name
- NCT02926300
- Testing
- stem cells
- Where
- 7 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Inflammatory Bowel Diseases, Crohns Disease
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Vedolizumab is a medicine that helps to reduce sensitivity and pain in the digestive system for participants with UC or CD. In this study, adults with UC or CD will be treated with vedolizumab according to their clinic's standard…
- Conditions
- Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative
- Trial name
- NCT04989907
- Where
- 6 sites in Switzerland
- Volunteers
- 92 people
- Sponsor
- Takeda
Crohn Disease (CD), Ulcerative Colitis (UC)
Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial
Fatigue is a big problem in people with inflammatory bowel disease (IBD). Even when IBD is well controlled, 50% of patients remain fatigued most of the time. Fatigue can be physical (e.g. feeling tired or weak) and mental (e.g.
- Conditions
- Crohn Disease (CD), Ulcerative Colitis (UC), Fatigue
- Trial name
- MFI (NCT07295834)
- Testing
- Modafinil
- Where
- 4 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- Imperial College London
Malignant Pleural Mesothelioma
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
This is a prospective study evaluating the effect of expression of CD74 and VEGF on outcome of treatment in patients with malignant pleural mesothelioma receiving Pemetrexed/Platinum protocol.
- Trial name
- NCT02761863
- Testing
- CD 74, VEGF detection
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Crohn's Disease
Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease
The study is being undertaken to evaluate whether delayed-release medications, designed to begin to open in the lower intestinal tract, the main site of Crohn's Disease, are more effective than standard systemically delivered…
- Trial name
- NCT00287170
- Testing
- Delayed Release 6MP or Calcitriol vs. Purinethol
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Teva GTC
Inflammatory Bowel Disease (IBD), Crohn's Disease
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland
The primary reason of this study is to observe current treatment options in participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Poland.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
- Trial name
- VARIETY (NCT05384080)
- Where
- 11 sites in Poland
- Volunteers
- 165 people
- Sponsor
- Takeda
Crohn Disease
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months.
- Trial name
- NCT03183661
- Testing
- ALLO-ASC-CD
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Anterogen Co., Ltd.
Obesity, Eating Disorders
Cognitive Therapy for Binge-Eating Disorder
The purpose of this study is to compare the efficacy of a CD-ROM-based cognitive-behavioral therapy (CBT) to traditional manual-based group therapy for obese individuals with binge-eating disorder (BED) and other unhealthy eating…
- Trial name
- NCT00050037
- Testing
- CBT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Myositis, Inclusion Body
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
This study will examine the safety and effectiveness of alemtuzumab (Campath® (Registered Trademark)) for improving muscle strength in patients with sporadic inclusion body myositis (s-IBM).
- Trial name
- NCT00079768
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Crohn Disease
Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
Anti-cytokine antibodies, such as Infliximab (an anti TNF alfa chimeric antibody) and Adalimumab (an anti TNF alfa humanize antibody), have been developed and used in clinical practice for the treatment of patients with Crohn…
- Trial name
- NCT02820493
- Testing
- vedolizumab
- Sponsor
- Universita degli Studi di Genova
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Inflammatory Bowel Diseases (IBD), Crohn Disease (CD)
NORDTREAT Prospective Study on Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), primarily ulcerative colitis (UC) and Crohn's disease (CD), is a chronic disease entity affecting individuals of all ages, and which may severely impact the lives of the patients and their…
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT05414578
- Where
- 17 sites in Denmark, Iceland and 2 more
- Volunteers
- 366 people
- Sponsor
- University of Southern Denmark
CD19+ Malignancies: Relapse Post-allogeneic Transplant
CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation
Eligible patients will receive escalating doses of 4G7-CARD T-cells paralleling clinical standard of care with unmanipulated donor lymphocytes. There are 3 intra-patient dose levels planned.
- Trial name
- CARD (NCT02893189)
- Testing
- Infusion of modified CAR19 T-cells (4G7-CARD T-cells)
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- University College, London
Multiple Myeloma
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
This is a multicenter, randomized, open label study designed to compare the efficacy and safety of lenalidomide with low-dose alkylating agents versus high-dose melphalan followed by stem cell support in newly diagnosed…
- Trial name
- NCT01091831
- Testing
- Cyclophosphamide, Lenalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 389 people
- Sponsor
- Fondazione EMN Italy Onlus
Crohns Disease
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
Advanced therapies including biologics and small molecules target specific inflammatory pathways. IBD's multifactorial etiology means that blocking a single pathway may not be sufficient for all patients.
- Trial name
- BOOST-CD (NCT06890637)
- Testing
- Fecal Microbial Transplantation, Crohns Disease Exclusion Diet, Advanced therapy
- Where
- 6 sites in India
- Volunteers
- 168 people
- Sponsor
- All India Institute of Medical Sciences
Celiac Disease
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
This is a phase 2b, multicenter, prospective, randomized, double-blind, placebo-controlled, crossover study in symptomatic celiac disease patients attempting a GFD for at least one year prior to screening.
- Trial name
- NCT04243551
- Testing
- Latiglutenase
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Entero Therapeutics